2020
DOI: 10.1001/jamadermatol.2019.4141
|View full text |Cite
|
Sign up to set email alerts
|

Targeted Inhibition of the Epidermal Growth Factor Receptor and Mammalian Target of Rapamycin Signaling Pathways in Olmsted Syndrome

Abstract: IMPORTANCEOlmsted syndrome is a rare and disabling genodermatosis for which no successful treatment is currently available. OBJECTIVE To evaluate the clinical response to the mammalian target of rapamycin (mTOR) inhibitor sirolimus and/or the epidermal growth factor receptor (EGFR) inhibitor erlotinib among patients with Olmsted syndrome. DESIGN, SETTING, AND PARTICIPANTSThis case series focused on 4 children with treatment-refractory Olmsted syndrome. These children received treatments (initiated in 2017 and … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
22
0
1

Year Published

2020
2020
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 26 publications
(26 citation statements)
references
References 15 publications
0
22
0
1
Order By: Relevance
“…TRPV3 is most abundantly expressed in skin keratinocytes and in cells surrounding hair follicles, where it plays an essential role in cutaneous sensation. RT-PCR or q-PCR analysis showing the absence of TRPV3 in human BMECs ( Golech et al, 2004 ; Hatano et al, 2013 ) and gain-of-function mutations in human TRPV3 are associated with Olmsted syndrome, which is characterized by severe palmoplantar and periorificial keratoderma ( Greco et al, 2020 ; Zhang et al, 2020 ). TRPV4 has been reported to be widely expressed throughout the brain including hippocampus, hypothalamus, cerebellum, lamina terminalis and optic chiasm, as well as a special enhanced expression in the olfactory placodes ( Mangos et al, 2007 ; Kauer and Gibson, 2009 ; Shibasaki et al, 2015 ).…”
Section: Discussionmentioning
confidence: 99%
“…TRPV3 is most abundantly expressed in skin keratinocytes and in cells surrounding hair follicles, where it plays an essential role in cutaneous sensation. RT-PCR or q-PCR analysis showing the absence of TRPV3 in human BMECs ( Golech et al, 2004 ; Hatano et al, 2013 ) and gain-of-function mutations in human TRPV3 are associated with Olmsted syndrome, which is characterized by severe palmoplantar and periorificial keratoderma ( Greco et al, 2020 ; Zhang et al, 2020 ). TRPV4 has been reported to be widely expressed throughout the brain including hippocampus, hypothalamus, cerebellum, lamina terminalis and optic chiasm, as well as a special enhanced expression in the olfactory placodes ( Mangos et al, 2007 ; Kauer and Gibson, 2009 ; Shibasaki et al, 2015 ).…”
Section: Discussionmentioning
confidence: 99%
“…This led the authors to propose the use of the EGFR inhibitor, with the aim of breaking the vicious circle initiated by the specific constitutive activation of TRPV3 36. The interest of such an innovative therapeutic approach was confirmed in four new patients with Olmsted syndrome linked to TRPV3 mutations 37…”
Section: Resultsmentioning
confidence: 99%
“…36 The interest of such an innovative therapeutic approach was confirmed in four new patients with Olmsted syndrome linked to TRPV3 mutations. 37…”
Section: Drug Repositioningmentioning
confidence: 99%
“…The therapeutic success of targeting the epidermal growth factor receptor (EGFR) in OS [ 27 , 86 ] supports a model in which EGFR stimulates keratinocyte differentiation into corneocytes. According to this concept, EGFR increases the activity of TRPV3, leading to influx of Ca 2+ from the extracellular space into the stratum granulosum.…”
Section: Introductionmentioning
confidence: 99%